晚期肝细胞癌的辅助治疗：从STORM研究取得进展
Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.
作者信息
Bouattour Mohamed, Soubrane Olivier, de Gramont Armand, Faivre Sandrine
机构信息
Department of Hepatology, Beaujon University Hospital, 100 boulevard du Général Leclerc, Clichy, 92110, France.
Surgery and Liver Transplant Department, Beaujon University Hospital, Clichy, France.
出版信息
Trials. 2016 Nov 25;17(1):563. doi: 10.1186/s13063-016-1675-8.
Abstract
UNLABELLED
Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical practice and future research.
TRIAL REGISTRATION
ClinicalTrials.gov: NCT00692770 . Registered 5 June 2008. This study has been completed.
摘要
未标注
与之前的其他治疗方法一样，抗血管生成药物索拉非尼在一项大型临床试验中未能显示出对肝细胞癌辅助治疗有任何益处。我们讨论了这些阴性结果的原因和影响以及对临床实践和未来研究的意义。
试验注册
ClinicalTrials.gov：NCT00692770。2008年6月5日注册。本研究已完成。
相似文献
1
Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.
Trials. 2016 Nov 25;17(1):563. doi: 10.1186/s13063-016-1675-8.
2
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.
3
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Trials. 2014 Dec 3;15:474. doi: 10.1186/1745-6215-15-474.
4
Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
Transplantation. 2014 Jul 15;98(1):100-6. doi: 10.1097/01.TP.0000441090.39840.b0.
5
Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
World J Gastroenterol. 2016 Jun 21;22(23):5384-92. doi: 10.3748/wjg.v22.i23.5384.
6
Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
World J Gastroenterol. 2016 Apr 7;22(13):3632-43. doi: 10.3748/wjg.v22.i13.3632.
7
Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
World J Gastroenterol. 2016 Apr 21;22(15):4034-40. doi: 10.3748/wjg.v22.i15.4034.
8
Management of hepatocellular carcinoma: an overview of major findings from meta-analyses.
Oncotarget. 2016 Jun 7;7(23):34703-51. doi: 10.18632/oncotarget.9157.
9
Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Clin Adv Hematol Oncol. 2016 Aug;14(8):585-7.
10
Liver tumors and loco-regional therapy.
Wien Med Wochenschr. 2013 Mar;163(5-6):107-8. doi: 10.1007/s10354-013-0188-2.
引用本文的文献
1
IMbrave050 Study: A Revolutionary Breakthrough in Hepatocellular Carcinoma Adjuvant Therapy.
J Clin Exp Hepatol. 2024 May-Jun;14(3):101360. doi: 10.1016/j.jceh.2024.101360. Epub 2024 Feb 3.
2
Image-guided chemistry altering biology: An in vivo study of thermoembolization.
PLoS One. 2018 Jul 16;13(7):e0200471. doi: 10.1371/journal.pone.0200471. eCollection 2018.
3
[Recent progress in nanomedicine for hepatocellular carcinoma therapy].
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2018 Apr 25;35(2):314-319. doi: 10.7507/1001-5515.201705008.
本文引用的文献
1
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.
2
Pragmatic issues in biomarker evaluation for targeted therapies in cancer.
Nat Rev Clin Oncol. 2015 Apr;12(4):197-212. doi: 10.1038/nrclinonc.2014.202. Epub 2014 Nov 25.
3
Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster.
Pharmacol Ther. 2014 Feb;141(2):117-24. doi: 10.1016/j.pharmthera.2013.09.003. Epub 2013 Sep 27.
4
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Cancer Res. 2004 Oct 1;64(19):7099-109. doi: 10.1158/0008-5472.CAN-04-1443.
5
Detection and clinical importance of micrometastatic disease.
J Natl Cancer Inst. 1999 Jul 7;91(13):1113-24. doi: 10.1093/jnci/91.13.1113.
Zotero 插件